Picture of Bayer AG logo

BAYN Bayer AG Share Price

0.000.00%
de flag iconLast trade - 00:00
HealthcareBalancedLarge CapValue Trap

Momentum

Relative Strength (%)
1m-4.76%
3m-14.91%
6m-48.83%
1yr-53.7%
Volume Change (%)
10d/3m-2.64%
Price vs... (%)
52w High-54.24%
50d MA-8.97%
200d MA-32.99%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)5.04
PEG Ratio (f)n/a
EPS Growth (f)-6.84%
Dividend Yield (f)6.71%
Valuation (ttm)IndustryMarket
Price to Book Value0.83
Price to Tang. Bookn/a
Price to Free Cashflown/a
Price to Sales0.58
EV to EBITDA6.02

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-0.17%
Return on Equity-9.82%
Operating Margin-0.3%

Financial Summary

Year End 31st DecUnit201820192020202120222023E2024ECAGR / Avg
Total Revenue€m36,74243,54541,40044,08150,73947,467.947,608.67.7%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-25.46-4.12n/an/a+84.94-25.65-6.84n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Bayer AG EPS forecast chart

Profile Summary

Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticala and Consumer Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Company is focusing on their oncology platform for Targeted Alpha Therapies for treating prostate cancer. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment has been moved to Cinven which operates as an independent company called Envu.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
January 15th, 1952
Public Since
November 28th, 1997
No. of Employees
100,873
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
de flag iconXETRA
Shares in Issue
982,424,082

BAYN Share Price Performance

Upcoming Events for BAYN

Q4 2023 Bayer AG Earnings Release

Q4 2023 Bayer AG Earnings Call

Bayer AG Capital Markets Day

Bayer AG Capital Markets Day

Bayer AG Annual Shareholders Meeting

Dividend For BAY.BA - 0.0000 EUR

Dividend For BAYGn.DE - 0.1100 EUR

Q1 2024 Bayer AG Earnings Release

Q2 2024 Bayer AG Earnings Release

FAQ